Skip to main content
Fig. 7 | Hereditas

Fig. 7

From: Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma

Fig. 7

Predictive efficacy of immunotherapy response for the CMLBS model. (A). The restricted mean survival (RMS) time difference by 6 months and 12 months after treatment between high- and low-CMLBS groups. (B). The long-term survival (LTS) difference after 3 months of treatment between high- and low-CMLBS groups. (C). The distribution of CMLBS in different immunotherapy response groups. (D) The TIDE algorithm predicts response to immunotherapy between high- and low-CMLBS groups. (E). Distribution of CMLBS in different immunotherapy response groups of GSE91061. (F). Kaplan-Meier survival curves for the GSE78220 cohort. (G). Kaplan-Meier survival curves for the GSE135222 cohort. (H). Kaplan-Meier survival curves for the GSE91061 cohort. (I-L). Comparisons of the IPS between high- and low-CMLBS groups

Back to article page

Hereditas

ISSN: 1601-5223

Contact us